Immunai is a groundbreaking brand that is revolutionizing the field of immunomodulatory therapeutics. With a deep understanding of the immune system and an engineering-first approach, Immunai is mapping the immune system at an unprecedented scale and granularity. Their platform, AMICA™ (Annotated Multiomic Immune Cell Atlas), combines multi-omic single cell analysis with machine learning and functional genomics to drive the development of next-generation immunomodulatory therapeutics.

Immunai also leverages their technology platform and patient-derived multi-omic data for target and therapeutic discovery. They collaborate with biopharmaceutical companies and academic research institutions at various stages of the drug discovery and development process. The Immunai team is a multidisciplinary group of immunologists, engineers, drug developers, computer scientists, and entrepreneurs who are singularly focused on bringing breakthrough medicines to patients.

Led by CEO and Co-Founder Noam Solomon, PhD, and supported by renowned leaders in the field such as Chief Science Officer Jacques Banchereau, PhD, the team combines their expertise to find and validate targets and therapeutics. Immunai is also actively seeking strategic partnerships with academic research institutions and biopharmaceutical companies to accelerate the development of novel therapeutics. With a shared vision of mapping the immune system, Immunai is committed to improving patient outcomes and pushing the boundaries of immunomodulatory drugs